{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:59:01Z","timestamp":1784303941448,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study aims to evaluate the adverse drug reactions associated with imiglucerase in the treatment of Gaucher disease by analyzing data from the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A comprehensive analysis was conducted on 166,800,135 adverse event reports from the FAERS database, covering the period from the first quarter of 2004 to the fourth quarter of 2023. The data were processed using R software and analyzed using multiple disproportionality methods, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS). These methodologies were applied to identify significant adverse reaction signals across various System Organ Classes (SOCs) and Preferred Terms (PTs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The analysis revealed significant adverse reaction signals in multiple SOCs, including general disorders and administration site conditions, injury, poisoning and procedural complications, infections and infestations, and nervous system disorders. Notably, general disorders and injury-related conditions had the highest number of reports. At the PT level, the term \"Gaucher disease\" yielded the highest statistical signal. This was identified as a critical reporting artifact, likely representing perceived treatment failure or disease progression, rather than a true adverse reaction. After accounting for this artifact, other significant adverse event signals included increased chitotriosidase, elevated acid phosphatase, and bone infarction, with musculoskeletal and connective tissue disorders being a key area of concern. A comparative analysis against other Gaucher therapies suggests this strong skeletal signal likely reflects confounding by indication rather than a drug-specific risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The findings underscore the importance of ongoing pharmacovigilance to monitor the safety of imiglucerase, especially among vulnerable populations such as pregnant women, long-term users, and those with comorbid hepatobiliary or skeletal conditions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03934-7","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T10:25:46Z","timestamp":1754562346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation and study of adverse reactions to imiglucerase based on the FAERS database"],"prefix":"10.1186","volume":"20","author":[{"given":"Pan","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"3934_CR1","doi-asserted-by":"crossref","unstructured":"Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18(2).","DOI":"10.3390\/ijms18020441"},{"issue":"18","key":"3934_CR2","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000;160(18):2835\u201343.","journal-title":"Arch Intern Med"},{"issue":"2","key":"3934_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/10245332.2016.1240391","volume":"22","author":"L Nalysnyk","year":"2017","unstructured":"Nalysnyk L, Rotella P, Simeone JC, Hamed A, Weinreb N. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2017;22(2):65\u201373.","journal-title":"Hematology"},{"issue":"17","key":"3934_CR4","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","volume":"129","author":"TM Cox","year":"2017","unstructured":"Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Goker-Alpan O, Watman N, et al. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. Blood. 2017;129(17):2375\u201383.","journal-title":"Blood"},{"issue":"1","key":"3934_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejogrb.2010.12.024","volume":"156","author":"S Granovsky-Grisaru","year":"2011","unstructured":"Granovsky-Grisaru S, Belmatoug N, vom Dahl S, Mengel E, Morris E, Zimran A. The management of pregnancy in Gaucher disease. Eur J Obstet Gynecol Reprod Biol. 2011;156(1):3\u20138.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"3934_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","volume":"36","author":"NJ Weinreb","year":"2013","unstructured":"Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, vom Dahl S, Hollak C. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis. 2013;36(3):543\u201353.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"3934_CR7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","volume":"71","author":"N Weinreb","year":"2007","unstructured":"Weinreb N, Barranger J, Packman S, Prakash-Cheng A, Rosenbloom B, Sims K, Angell J, Skrinar A, Pastores GM. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet. 2007;71(6):576\u201388.","journal-title":"Clin Genet"},{"issue":"8","key":"3934_CR8","doi-asserted-by":"publisher","first-page":"ziae071","DOI":"10.1093\/jbmrpl\/ziae071","volume":"8","author":"A Barbato","year":"2024","unstructured":"Barbato A, Vergatti A, Giaquinto A, Pizzulo IL, Perna L, Perruolo G, Abate V, Sibilio M, Mainolfi C, Soscia E, et al. Imiglucerase, cholecalciferol, and bone-diet in skeletal health management of type I Gaucher disease patients: a pilot study and systematic review. JBMR Plus. 2024;8(8):ziae071.","journal-title":"JBMR Plus"},{"issue":"7","key":"3934_CR9","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803.","journal-title":"Int J Med Sci"},{"issue":"5","key":"3934_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40264-015-0281-0","volume":"38","author":"JC Bouvy","year":"2015","unstructured":"Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38(5):437\u201353.","journal-title":"Drug Saf"},{"issue":"7","key":"3934_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","volume":"16","author":"YM Alatawi","year":"2017","unstructured":"Alatawi YM, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2017;16(7):761\u20137.","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"3934_CR12","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/ajh.26276","volume":"96","author":"PK Mistry","year":"2021","unstructured":"Mistry PK, Lukina E, Ben Turkia H, Shankar SP, Baris Feldman H, Ghosn M, Mehta A, Packman S, Lau H, Petakov M, et al. Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: phase 3 ENGAGE trial final results. Am J Hematol. 2021;96(9):1156\u201365.","journal-title":"Am J Hematol"},{"issue":"1","key":"3934_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40264-013-0124-9","volume":"37","author":"I Aw","year":"2014","unstructured":"Aw I, Pratt NL, Kalisch LM, Roughead EE. Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia. Drug Saf. 2014;37(1):53\u201364.","journal-title":"Drug Saf"},{"key":"3934_CR14","doi-asserted-by":"publisher","first-page":"1377679","DOI":"10.3389\/fphar.2024.1377679","volume":"15","author":"E Bao","year":"2024","unstructured":"Bao E, Yang Y, Jiang B, Wang B, Liu Y, Yang L, Xia L, Zhu P. An exploratory study evaluated the 30 most commonly reported medications in the United States food and drug administration\u2019s adverse event reporting system that are associated with the occurrence of kidney stones. Front Pharmacol. 2024;15:1377679.","journal-title":"Front Pharmacol"},{"key":"3934_CR15","doi-asserted-by":"crossref","unstructured":"Park J, Kim D, Song TJ: A disproportionality analysis for association of systemic capillary leak syndrome with COVID-19 vaccination using the world health organization pharmacovigilance database. Vaccines (Basel). 2022;10(6).","DOI":"10.3390\/vaccines10060835"},{"issue":"6","key":"3934_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf. 2002;25(6):381\u201392.","journal-title":"Drug Saf"},{"key":"3934_CR17","doi-asserted-by":"crossref","unstructured":"Zheng J, Zhang Z, Liang Y, Wu Q, Din C, Wang Y, Ma L, Su L. Risk of congenital anomalies associated with psychotropic medications: a review of neonatal reports in the FDA adverse event reporting System (FAERS). Arch Womens Ment Health. 2024.","DOI":"10.21203\/rs.3.rs-4333094\/v1"},{"key":"3934_CR18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0011-393X(01)80071-0","volume":"62","author":"A Szarfman","year":"2001","unstructured":"Szarfman A, O\u2019Neill R. Some US food and drug administration perspectives on data mining for pediatric safety assessment. Curr Therap Res-Clin Exp. 2001;62:650\u201363.","journal-title":"Curr Therap Res-Clin Exp"},{"issue":"7","key":"3934_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1310\/hpj5107-553","volume":"51","author":"A Van Rossum","year":"2016","unstructured":"Van Rossum A, Holsopple M. Enzyme replacement or substrate reduction? A review of Gaucher disease treatment options. Hosp Pharm. 2016;51(7):553\u201363.","journal-title":"Hosp Pharm"},{"issue":"1","key":"3934_CR20","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/s13023-021-02119-2","volume":"16","author":"R Sagara","year":"2021","unstructured":"Sagara R, Ishigaki M, Otsuka M, Murayama K, Ida H, Fernandez J. Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan. Orphanet J Rare Dis. 2021;16(1):502.","journal-title":"Orphanet J Rare Dis"},{"key":"3934_CR21","unstructured":"Sanofi. Cerezyme (imiglucerase) prescribing information. Accessed July 28, 2025. https:\/\/products.sanofi.us\/cerezyme\/cerezyme.pdf"},{"issue":"9645","key":"3934_CR22","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher\u2019s disease. Lancet. 2008;372(9645):1263\u201371.","journal-title":"Lancet"},{"issue":"2","key":"3934_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00431-003-1362-0","volume":"163","author":"GA Grabowski","year":"2004","unstructured":"Grabowski GA, Andria G, Baldellou A, Campbell PE, Charrow J, Cohen IJ, Harris CM, Kaplan P, Mengel E, Pocovi M, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr. 2004;163(2):58\u201366.","journal-title":"Eur J Pediatr"},{"key":"3934_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/CE.S93717","volume":"11","author":"C Serratrice","year":"2016","unstructured":"Serratrice C, Carballo S, Serratrice J, Stirnemann J. Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy. Core Evid. 2016;11:37\u201347.","journal-title":"Core Evid"},{"issue":"2","key":"3934_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ymgme.2013.03.015","volume":"109","author":"DJ Sillence","year":"2013","unstructured":"Sillence DJ. Glucosylceramide modulates endolysosomal pH in Gaucher disease. Mol Genet Metab. 2013;109(2):194\u2013200.","journal-title":"Mol Genet Metab"},{"key":"3934_CR26","doi-asserted-by":"crossref","unstructured":"Zeng Y, Chen Z, Luo Y, Luo J, Shi L, Zhou X. Mining and disproportionality analysis of adverse events signals for naltrexone based on real-world data from the FAERS database. Expert Opin Drug Saf. 2025:1\u20138.","DOI":"10.1080\/14740338.2025.2461200"},{"key":"3934_CR27","volume":"31","author":"NC Lee","year":"2022","unstructured":"Lee NC, Chien YH, Wang CH, Wong SL, Peng SS, Tsai FJ, Hwu WL. Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3. Mol Genet Metab Rep. 2022;31: 100867.","journal-title":"Mol Genet Metab Rep"},{"issue":"7","key":"3934_CR28","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/ajh.24007","volume":"90","author":"D Elstein","year":"2015","unstructured":"Elstein D, Mehta A, Hughes DA, Giraldo P, Charrow J, Smith L, Shankar SP, Hangartner TN, Kunes Y, Wang N, et al. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease. Am J Hematol. 2015;90(7):592\u20137.","journal-title":"Am J Hematol"},{"issue":"4","key":"3934_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ymgme.2021.02.004","volume":"132","author":"VL Gremminger","year":"2021","unstructured":"Gremminger VL, Harrelson EN, Crawford TK, Ohler A, Schulz LC, Rector RS, Phillips CL. Skeletal muscle specific mitochondrial dysfunction and altered energy metabolism in a murine model (oim\/oim) of severe osteogenesis imperfecta. Mol Genet Metab. 2021;132(4):244\u201353.","journal-title":"Mol Genet Metab"},{"key":"3934_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.773135","volume":"12","author":"X Ji","year":"2021","unstructured":"Ji X, Cui G, Xu C, Hou J, Zhang Y, Ren Y. Combining a pharmacological network model with a bayesian signal detection algorithm to improve the detection of adverse drug events. Front Pharmacol. 2021;12: 773135.","journal-title":"Front Pharmacol"},{"issue":"2","key":"3934_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0002-9343(80)90363-0","volume":"68","author":"RI Horwitz","year":"1980","unstructured":"Horwitz RI, Feinstein AR. The problem of \u201cprotopathic bias\u201d in case-control studies. Am J Med. 1980;68(2):255\u20138.","journal-title":"Am J Med"},{"issue":"2","key":"3934_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40801-018-0131-3","volume":"5","author":"T Misu","year":"2018","unstructured":"Misu T, Kortepeter CM, Mu\u00f1oz MA, Wu E, Dal Pan GJ. An evaluation of \u201cdrug ineffective\u201d postmarketing reports in drug safety surveillance. Drugs Real World Outcomes. 2018;5(2):91\u20139.","journal-title":"Drugs Real World Outcomes"},{"issue":"1","key":"3934_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bcmd.2011.09.009","volume":"48","author":"D Elstein","year":"2012","unstructured":"Elstein D, Altarescu G, Maayan H, Phillips M, Abrahamov A, Hadas-Halpern I, Tiomkin M, Zimran A. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem. Blood Cells Mol Dis. 2012;48(1):45\u201350.","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"3934_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymgme.2015.05.012","volume":"117","author":"L Smith","year":"2016","unstructured":"Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Lee HM, et al. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 na\u00efve to enzyme replacement therapy or previously treated with imiglucerase. Mol Genet Metab. 2016;117(2):164\u201371.","journal-title":"Mol Genet Metab"},{"key":"3934_CR35","doi-asserted-by":"crossref","unstructured":"Zimran A, Szer J, Becker-Cohen M, Jens S, Cozma C, Revel-Vilk S. The bone biomarker of quantitative chemical shift imaging in patients with type 1 Gaucher disease receiving low-dose long-term enzyme replacement therapy. J Clin Med. 2023; 12(6).","DOI":"10.3390\/jcm12062220"},{"key":"3934_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1750-1172-7-77","volume":"7","author":"J Stirnemann","year":"2012","unstructured":"Stirnemann J, Vigan M, Hamroun D, Heraoui D, Rossi-Semerano L, Berger MG, Rose C, Camou F, de Roux-Serratrice C, Grosbois B, et al. The French Gaucher\u2019s disease registry: clinical characteristics, complications and treatment of 562 patients. Orphanet J Rare Dis. 2012;7:77.","journal-title":"Orphanet J Rare Dis"},{"key":"3934_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2022.102705","volume":"98","author":"MD Cappellini","year":"2023","unstructured":"Cappellini MD, Carubbi F, Di Rocco M, Giona F, Giuffrida G. Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: a sub-study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Blood Cells Mol Dis. 2023;98: 102705.","journal-title":"Blood Cells Mol Dis"},{"issue":"1\u20132","key":"3934_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jim.2011.07.020","volume":"373","author":"M S\u00e9llos-Moura","year":"2011","unstructured":"S\u00e9llos-Moura M, Barzegar S, Pan L, Shi P, Oommen S, Durant J, Ruiz JA. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease. J Immunol Methods. 2011;373(1\u20132):45\u201353.","journal-title":"J Immunol Methods"},{"key":"3934_CR39","doi-asserted-by":"crossref","unstructured":"Szyma\u0144ska-Ro\u017cek P, Czartoryska B, Kleinotiene G, Lipi\u0144ski P, Tylki-Szyma\u0144ska A, \u0141ugowska A. A 20-year longitudinal study of plasma chitotriosidase activity in treated gaucher disease type 1 and 3 patients-a qualitative and quantitative approach. Biomolecules. 2023;13(3).","DOI":"10.3390\/biom13030436"},{"issue":"4","key":"3934_CR40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00109-021-02174-z","volume":"100","author":"J Roh","year":"2022","unstructured":"Roh J, Subramanian S, Weinreb NJ, Kartha RV. Gaucher disease\u2014more than just a rare lipid storage disease. J Mol Med (Berl). 2022;100(4):499\u2013518.","journal-title":"J Mol Med (Berl)"},{"issue":"3","key":"3934_CR41","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bcmd.2009.04.003","volume":"43","author":"A Zimran","year":"2009","unstructured":"Zimran A, Morris E, Mengel E, Kaplan P, Belmatoug N, Hughes DA, Malinova V, Heitner R, Sobreira E, Mrsi\u0107 M, et al. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis. 2009;43(3):264\u201388.","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"3934_CR42","first-page":"53","volume":"16","author":"SR Giannubilo","year":"2015","unstructured":"Giannubilo SR, Pasculli A, Tidu E, Ciavattini A. Replacement therapy for Gaucher disease during pregnancy: a case report. J Reprod Infertil. 2015;16(1):53\u20137.","journal-title":"J Reprod Infertil"},{"key":"3934_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2020.101667","volume":"44\u201345","author":"M Guarino","year":"2020","unstructured":"Guarino M, Cossiga V, Morisco F. The interpretation of liver function tests in pregnancy. Best Pract Res Clin Gastroenterol. 2020;44\u201345: 101667.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"3934_CR44","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/blood.V120.21.2132.2132","volume":"120","author":"D Christoulas","year":"2012","unstructured":"Christoulas D, Kolomodi D, Terpos E, Voskaridou E, Dimopoulos M, Komninaka V, Marinakis T, Repa K. Replacement therapy with imiglucerase improves magnetic resonance imaging (MRI) abnormalities in almost half patients with non-neuronopathic form of gaucher disease after twelve months of therapy: results of a semi-quantitative MRI method. Blood. 2012;120:2132\u20132132.","journal-title":"Blood"},{"key":"3934_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2022.102705","volume":"98","author":"M Cappellini","year":"2022","unstructured":"Cappellini M, Carubbi F, Di Rocco M, Giona F, Giuffrida G. Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: a sub-study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Blood Cells Mol Dis. 2022;98: 102705.","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"3934_CR46","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/14740338.2024.2429475","volume":"24","author":"Z Wang","year":"2025","unstructured":"Wang Z, Zheng F, Wan L, Zhang L, Xiong S, Li S, Wang C, Liu X, Deng J. Safety assessment of cabozantinib in patients with renal cell carcinoma: retrospective pharmacovigilance study based on FAERS database. Expert Opin Drug Saf. 2025;24(4):427\u201333.","journal-title":"Expert Opin Drug Saf"},{"key":"3934_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.104517","volume":"135","author":"K Kreimeyer","year":"2021","unstructured":"Kreimeyer K, Dang O, Spiker J, Mu\u00f1oz MA, Rosner G, Ball R, Botsis T. Feature engineering and machine learning for causality assessment in pharmacovigilance: lessons learned from application to the FDA adverse event reporting system. Comput Biol Med. 2021;135: 104517.","journal-title":"Comput Biol Med"},{"issue":"1","key":"3934_CR48","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/jmp\/jhae038","volume":"50","author":"A Due","year":"2025","unstructured":"Due A. Is there a \u201cbest\u201d way for patients to participate in pharmacovigilance? J Med Philos. 2025;50(1):46\u201356.","journal-title":"J Med Philos"},{"issue":"10","key":"3934_CR49","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jval.2020.06.006","volume":"23","author":"BA Feinberg","year":"2020","unstructured":"Feinberg BA, Gajra A, Zettler ME, Phillips TD, Phillips EG Jr, Kish JK. Use of real-world evidence to support FDA approval of oncology drugs. Value Health. 2020;23(10):1358\u201365.","journal-title":"Value Health"},{"issue":"2","key":"3934_CR50","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","volume":"132","author":"NJ Weinreb","year":"2021","unstructured":"Weinreb NJ, Camelo JS Jr, Charrow J, McClain MR, Mistry P, Belmatoug N. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. Mol Genet Metab. 2021;132(2):100\u201311.","journal-title":"Mol Genet Metab"},{"key":"3934_CR51","doi-asserted-by":"crossref","unstructured":"Shemesh E, Deroma L, Bembi B, Deegan P, Hollak C, Weinreb NJ, Cox TM. Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database Syst Rev. 2015;(3):CD010324.","DOI":"10.1002\/14651858.CD010324.pub2"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03934-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03934-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03934-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:41:06Z","timestamp":1757346066000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03934-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3934"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03934-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"24 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no conflicts of interest regarding this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"406"}}